Silence Therapeutics (SLN) Set to Announce Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN) is projected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Silence Therapeutics to post earnings of ($0.1129) per share and revenue of $0.11 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 2:00 AM ET.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. On average, analysts expect Silence Therapeutics to post ($0.82) EPS for the current fiscal year and ($0.94) EPS for the next fiscal year.

Silence Therapeutics Stock Up 0.1%

NASDAQ SLN opened at $19.76 on Tuesday. The firm’s 50 day moving average is $13.61 and its 200-day moving average is $9.11. The company has a market capitalization of $1.19 billion, a PE ratio of -15.44 and a beta of 1.45. Silence Therapeutics has a 12-month low of $4.19 and a 12-month high of $19.86.

Analyst Ratings Changes

Several brokerages recently commented on SLN. William Blair cut shares of Silence Therapeutics from an “outperform” rating to a “hold” rating in a report on Monday, October 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Thursday, October 15th. Jefferies Financial Group lowered shares of Silence Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 price target on the stock. in a research note on Monday, October 19th. HC Wainwright cut shares of Silence Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $75.00 to $20.00 in a research report on Wednesday, October 21st. Finally, Chardan Capital downgraded Silence Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $24.00.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use small interfering RNA (siRNA) to selectively reduce the production of disease-related proteins. Its approach is designed to intervene at the genetic messenger RNA stage, potentially providing targeted and durable effects for patients with serious diseases.

The company’s proprietary mRNAi GOLD platform supports the design and delivery of siRNA medicines, including compounds intended to target tissues such as the liver.